RT Journal Article SR Electronic T1 Trends and variation in unsafe prescribing of methotrexate: a cohort study in English NHS primary care JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19000919 DO 10.1101/19000919 A1 Brian MacKenna A1 Helen J Curtis A1 Alex J Walker A1 Richard Croker A1 Seb Bacon A1 Ben Goldacre YR 2019 UL http://medrxiv.org/content/early/2019/07/02/19000919.abstract AB Objective To describe trends and geographical variation in methotrexate prescribing that breaches national safety recommendations; deaths from methotrexate poisoning; and associated litigation.Methods A retrospective cohort study of English NHS primary care prescribing data, complemented by information obtained through Freedom of Information (FOI) requests. The main outcome measures were: (1) variation in ratio of breaching / adherent prescribing, geographically and over time, between General Practices and Clinical Commissioning Groups; (2) description of responses to FOI requests.Results Out of 7349 NHS General Practices in England, 1689 practices prescribed both 2.5mg and 10mg tablets to individual patients in 2017, breaching national guidance. In April 2018, 697 practices (at the 90th centile and above) prescribed at least 14.3% of all methotrexate as 10mg tablets, breaching national guidance. The 66 practices at the 99th percentile and above gave at least 52.4% of all prescribed methotrexate in the form of 10 mg tablets. The prescribing of 10mg tablets has fallen over 7 years, with 10mg tablets as a proportion of all methotrexate tablets falling from 9.1% to 3.4%. 21 deaths caused by methotrexate poisoning have been reported from 1993-2017.Conclusions The prevalence of unsafe methotrexate prescribing has reduced but it remains common, with substantial variation between organisations. We recommend the NHS invests in better strategies around implementation of safety recommendations. 21 deaths have been attributed to methotrexate poisoning but with no further details easily available: the full coroners reports for these deaths should be reviewed to identify recurring themes.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/conflicts-of-interest/ and declare the following: BG has received research funding from the Laura and John Arnold Foundation, the Wellcome Trust, the Oxford Biomedical Research Centre, the NHS National Institute for Health Research School of Primary Care Research, the Health Foundation and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. RC, AJW, HC, SB are employed on BG’s grants for OpenPrescribing. BM is seconded to the DataLab from NHS England.Funding StatementNo specific funding was obtained for this project. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.NAAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.NAI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData are available in a public, open access repository on Github https://github.com/ebmdatalab/Methotrexate/releases/tag/v1.0 and Figshare https://figshare.com/collections/Methotrexate/4542308/1https://github.com/ebmdatalab/Methotrexate/releases/tag/v1.0https://figshare.com/collections/Methotrexate/4542308/1